Clinical trials: T2DM (Type 2 Diabetes Mellitus)
Type 2 Diabetes Mellitus (T2DM)
THE EFFECT OF BITTER ORANGE (CITRUS AURANTIUM) OIL AROMATHERAPY ON SLEEP QUALITY AND FATIGUE LEVELS
This study will be conducted to examine the effect of bitter orange oil inhalation aromatherapy on sleep quality and fatigue levels in patients with Type 2 Diabetes Mellitus (DM).
- Trial name
- NCT07756151
- Testing
- bitter orange oil group
- Volunteers
- 100 people
- Sponsor
- Uludag University
Chronic Kidney Disease(CKD), Type 2 DM
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)
IRIS-CKD is an implementation study to improve guideline-recommended screening of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
- Conditions
- Chronic Kidney Disease(CKD), Type 2 DM, Type 2 Diabetes Mellitus (T2DM)
- Trial name
- IRIS-CKD (NCT06906627)
- Testing
- (IRIS-CKD Screening Program): Home Kit, (IRIS-CKD Screening Program): Standard Lab Order
- Where
- 7 sites in United States
- Volunteers
- 500 people
- Sponsor
- Duke University
Type 2 Diabetes Mellitus
A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients
Primary Objectives: To assess in overweight to obese T2DM patients: The glucagon receptor occupancy of SAR425899 at two dose levels in the human liver with positron-emission tomography (PET) imaging using…
- Trial name
- NCT03350191
- Testing
- SAR425899, [68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer), [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)
- Where
- Sweden
- Volunteers
- 13 people
- Sponsor
- Sanofi
T2DM (Type 2 Diabetes Mellitus)
The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus
The purpose of this study is to determine the efficacy and safety of DWP16001 compared to active drug in the treatment of type 2 diabetes mellitus.
- Trial name
- NCT04654390
- Testing
- DWP16001 Amg
- Where
- South Korea
- Volunteers
- 270 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes
A Study of HS-20094 in Patients With T2DM
This is a 32-week, phase 2, randomized study, HS-20094 and placebo were double-blind, dulaglutide was open-label. Adults with T2D inadequately controlled with diet and exercise alone or with stable metformin, an HbA1c (glycated…
- Trial name
- NCT06901648
- Testing
- HS-20094, Dulaglutide, Palcebo
- Where
- China
- Volunteers
- 275 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus, Cardiovascular Disease
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
This study is carried out to assess whether dapagliflozin improves glycemic control, decreases fasting plasma glucose levels, body weight and blood pressure when added to patient's existing medications and how it compares with…
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Disease, Inadequate Glycaemic Control
- Trial name
- NCT01042977
- Testing
- Dapagliflozin
- Where
- 135 sites in United States, Argentina and 8 more
- Volunteers
- 964 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DM
Type 2 diabetes mellitus is a complex, chronic disease that requires a comprehensive treatment plan aimed at meeting multitude therapeutic targets associated with micro- and macro-vascular risk reduction.
- Trial name
- NCT03090464
- Testing
- Use of digital disease management tool
- Where
- 46 sites in United States
- Volunteers
- 328 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Coronary Artery Disease
SMBG Protocols Predicting Glucose Levels in Senior Diabetes Mellitus With CAD
Self-monitoring of blood glucose (SMBG) is a common way to assess glycemic control in diabetes management. Multiple times of blood glucose measurements by fingerstick in the same day are of tough challenge to it.
- Trial name
- NCT01954771
- Testing
- SMBG, CGMS
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Beijing Anzhen Hospital
Diabetes Mellitus, Type 2
4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)
The objective of this trial is to evaluate the pharmacodynamics, pharmacokinetics, safety, and tolerability of once daily oral administration of BI 10773 administered for 28 days in Japanese patients with T2DM.
- Trial name
- NCT00885118
- Testing
- BI 10773
- Where
- 5 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus (T2DM)
Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus
Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus
- Trial name
- NCT07187856
- Testing
- PG-102, Semaglutide
- Where
- Australia
- Volunteers
- 80 people
- Sponsor
- ProGen. Co., Ltd.
Type 2 Diabetes Mellitus
Physiologic Insulin Resensitization (PIR) Treatment in Patients With a Diagnosis of Type 2 Diabetes Mellitus (T2DM)
The purpose of the study is to assess the outcomes of Physiologic Insulin Resensitization (PIR) treatment compared to standard of care (SOC) on patients with a diagnosis of Type 2 diabetes mellitus (T2DM).
- Trial name
- (PIR) (NCT07906470)
- Testing
- Physiologic insulin resensitization (PIR)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Alabama at Birmingham
Diabetes Mellitus, Non Alcholic Fatty Liver Disease
Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).
Nonalcoholic fatty liver disease (NAFLD) encompasses conditions such as nonalcoholic steatohepatitis (NASH), which involves liver inflammation and fibrosis resulting from steatosis, potentially leading to cirrhosis and…
- Trial name
- NCT07020377
- Testing
- Dapagliflozin (DAPA), Negative control
- Where
- 2 sites in Egypt
- Volunteers
- 60 people
- Sponsor
- Amira Bisher,PhD
Type 2 Diabetes, Atherosclerosis
The Copenhagen Insulin and Metformin Therapy Trial
Type 2 Diabetes Mellitus patients (T2DM) have an increased mortality rate due to macrovascular disease. The primary objective of the study is to evaluate the effect of an 18-month treatment with metformin versus placebo in…
- Conditions
- Type 2 Diabetes, Atherosclerosis, Arteriosclerosis
- Trial name
- CIMT (NCT00657943)
- Testing
- metformin, insulin detemir, insulin aspart + insulin aspart protamin
- Where
- 9 sites in Denmark
- Volunteers
- 415 people
- Sponsor
- Steno Diabetes Center Copenhagen
Diabetes Mellitus Type 2 (T2DM)
Efect Supplementation Vitamin D in Diabetes Mellitus Type 2
This is double blind randomized controlled trial study using 92 subject with diabetes mellitus type 2divided into 2 group, one group as control and other group as vitamin D group.
- Trial name
- NCT07019415
- Where
- Indonesia
- Volunteers
- 92 people
- Sponsor
- Trisakti University
Type 2 Diabetes
Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM
To compare efficacy, safety and durability of combination therapy with pioglitazone plus GLP-1 RA versus basal bolus insulin in poorly controlled T2DM patients on metformin plus sulfonylurea
- Trial name
- NCT02887625
- Testing
- Pioglitazone plus exenatide, insulin glargine and insulin aspart
- Where
- Qatar
- Volunteers
- 410 people
- Sponsor
- Dr. Muhammad Abdulghani
Type 2 Diabetes Mellitus (T2DM), Sarcopenia
HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide
This randomized, double-blind, placebo-controlled trial will evaluate whether daily calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB) plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Sarcopenia, Obesity, Muscle Loss
- Trial name
- PRESERVE-HMB (NCT07760948)
- Testing
- Calcium-HMB Plus Vitamin D3
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Vanderbilt University Medical Center
Type 2 Diabetes Mellitus, Overweight
Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic Patients
Besides their potential action in the treatment of type 2 diabetes mellitus (T2DM), GLP-1 analogues decrease satiety and food intake leading to a significant weight loss in patients.
- Trial name
- NCT01599338
- Testing
- Liraglutide
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Type 2 Diabetes Mellitus
A Study to Compare the Use of Diabetes Treatment Support System (BAP0527 and Blood Glucose Meter) in Addition to Daily Practice and Treatment With Daily Practice and Treatment Alone in Patients With Type 2 Diabetes Mellitus
The subjects of this study are patients with type 2 diabetes mellitus. The patients take part in dietetic therapy and exercise therapy, and also receive diabetes education to improve lifestyle habits, but since diet and exercise…
- Trial name
- NCT06156696
- Testing
- BAP0527, Blood Glucose Meter
- Where
- Japan
- Volunteers
- 248 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to placebo in participants with type 2 diabetes that are already on insulin glargine, with or without metformin.
- Trial name
- SURPASS-5 (NCT04039503)
- Testing
- Tirzepatide
- Where
- 48 sites in United States, Czechia and 6 more
- Volunteers
- 475 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Cognitive Functions Confusion
Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)
Type 2 diabetes is associated with diabetic cognopathy, the prevalence of Alzheimer's Disease(AD) in T2DM patients is 1.5 to 2.5 times higher than the general population.
- Trial name
- ESCDP (NCT04304261)
- Testing
- Canagliflozin, Sitagliptin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Third Military Medical University